[Treatment of true precocious puberty with medroxyprogesterone acetate].
The authors analyze the treatment of 16 female infants with true precocious puberty, ages ranging from 12 months to 9.5 years at the time of diagnosis, based on clinical and laboratory findings. All patients were treated with 150 to 300 mg. every 15 to 20 days of injectable medroxyprogesterone acetate (MPA) for periods from 5 months to 6 years. The prognosis of the adult height was evaluated before and during MPA treatment using the following parameters: height velocity as a function of bone age (good response of 15 patients); height as a function of bone age (good response of 13 patients); developmental quotient (good response of 14 patients), and adult height prognosis by the use of the tables of Bayley & Pinneau (good response of 8 out of 10 patients). The authors conclude that MPA treatment was effective in improving the prognosis of adult height in 14 out of 16 patients of true precocious puberty.
D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D011629:Puberty, Precocious / Q000188:drug therapy*
D008525:Medroxyprogesterone
Tratamiento de la pubertad precoz verdadera con acetato de medroxiprogesterona.